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ABSTRACT A major challenge in finding a cure for HIV-1/AIDS is the difficulty in
identifying and eradicating persistent reservoirs of replication-competent provirus.
Long noncoding RNAs (lncRNAs, 200 nucleotides) are increasingly recognized to
play important roles in pathophysiology. Here, we report the first genome-wide ex-
pression analysis of lncRNAs in HIV-1-infected primary monocyte-derived macro-
phages (MDMs). We identified an lncRNA, which we named HIV-1-enhanced lncRNA
(HEAL), that is upregulated by HIV-1 infection of MDMs, microglia, and T lympho-
cytes. Peripheral blood mononuclear cells of HIV-1-infected individuals show ele-
vated levels of HEAL. Importantly, HEAL is a broad enhancer of multiple HIV-1 strains
because depletion of HEAL inhibited X4, R5, and dual-tropic HIV replications and the
inhibition was rescued by HEAL overexpression. HEAL forms a complex with the
RNA-binding protein FUS, which facilitates HIV replication through at least two
mechanisms: (i) HEAL-FUS complex binds the HIV promoter and enhances recruit-
ment of the histone acetyltransferase p300, which positively regulates HIV transcrip-
tion by increasing histone H3K27 acetylation and P-TEFb enrichment on the HIV
promoter, and (ii) HEAL-FUS complex is enriched at the promoter of the cyclin-
dependent kinase 2 gene, CDK2, to enhance CDK2 expression. Notably, HEAL knock-
down and knockout mediated by RNA interference (RNAi) and CRISPR-Cas9, respec-
tively, prevent HIV-1 recrudescence in T cells and microglia upon cessation of
azidothymidine treatment in vitro. Our results suggest that silencing of HEAL or per-
turbation of the HEAL-FUS ribonucleoprotein complex could provide a new epige-
netic silencing strategy to eradicate viral reservoirs and effect a cure for HIV-1/AIDS.
IMPORTANCE Despite our increased understanding of the functions of lncRNAs,
their potential to develop HIV/AIDS cure strategies remains unexplored. A genome-
wide analysis of lncRNAs in HIV-1-infected primary monocyte-derived macrophages
(MDMs) was performed, and 1,145 differentially expressed lncRNAs were identi-
fied. An lncRNA named HIV-1-enhanced lncRNA (HEAL) is upregulated by HIV-1
infection and promotes HIV replication in T cells and macrophages. HEAL forms a
complex with the RNA-binding protein FUS to enhance transcriptional coactiva-
tor p300 recruitment to the HIV promoter. Furthermore, HEAL knockdown and
knockout prevent HIV-1 recrudescence in T cells and microglia upon cessation of
azidothymidine treatment, suggesting HEAL as a potential therapeutic target to
cure HIV-1/AIDS.
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Human immunodeficiency virus type 1 (HIV-1) is a pathogenic retrovirus and thecausative agent of AIDS and AIDS-related disorders. There were 1.7 million new
infections globally in 2018, and 38 million people are currently living with HIV-1 (1).
Although the introduction of antiretroviral therapy (ART) has prevented millions of
AIDS-related deaths worldwide, patients must continue to receive ART for the remain-
der of their lives. HIV-1 reservoirs persist even while subjects are on ART, leading to a
rapid increase in viral replication when therapy is discontinued (2). Therefore, eradica-
tion of persistent HIV-1 reservoirs remains the main barrier to achieving a cure for
HIV-1/AIDS.
The prevailing view of persistence suggests that the virus remains in a latent state
in memory CD4 T cells regardless of plasma viral loads, allowing the virus to establish
a lifelong infection in the host (3–5). Since the latent virus is refractory to existing
antiretroviral therapies, curative strategies are now focusing on agents that reactivate
viral replication and render it susceptible to conventional therapy. Any strategy aimed
at controlling and eradicating viral reservoirs in HIV-1-infected individuals must target
such latent reservoirs (6). In addition to CD4 T cells, cells of the monocyte/macro-
phage lineage are well-established HIV-1 hosts (7–9). HIV-1-infected macrophages have
been identified in the spinal cord, lymph nodes, and lung (10, 11). Because of the
challenges in analyzing tissue macrophages, however, their contribution to viral repli-
cation and persistence has been difficult to assess.
The mammalian genome contains thousands of long noncoding RNAs (lncRNAs,
200 nucleotides), including intergenic lncRNAs (lincRNAs), which are increasingly
recognized to play major roles in gene regulation (12). lncRNAs are transcribed in cells,
but they lack protein-encoding potential (13, 14). It is estimated that the number of
lncRNAs in humans ranges from 20,000 to over 100,000 (15, 16). The pathophysiological
functions and mechanisms of lncRNAs in gene regulation have started to emerge (17,
18). lncRNA loci can regulate gene expression in a cis or trans manner, and these
classifications provide a basic framework to design experimental approaches and
understand lncRNA functions (19).
Work over the last few years has begun to uncover the role of lncRNAs in modu-
lating HIV-1 gene expression (20–23; reviewed in reference 24). The first evidence that
lncRNAs might be involved in HIV-1 replication came from experiments in the Jurkat T
cell line, in which knockdown (KD) of NEAT1 increased viral production by enhancing
the nuclear export of Rev-dependent instability element (INS)-containing HIV-1 mRNAs
(23). RNA interference (RNAi)-mediated silencing of an lncRNA, NRON, increased HIV-1
replication by stimulating NFAT (nuclear factor of activated T cells) and viral long
terminal repeat (LTR) activities (21). In addition, NRON has been reported to suppress
viral transcription by inducing Tat protein degradation, thus contributing to HIV-1
latency (25). An lncRNA, uc002yug.2, has been reported to activate latent HIV-1
replication through RUNX 1b/1c regulation and promoting Tat protein expression (20).
Another lincRNA, MALAT1 (metastasis-associated lung adenocarcinoma transcript 1),
promotes HIV transcription apparently by displacing the polycomb repressive complex
2 (PRC2) (26). Further, deep sequencing of HIV-1-infected CD4 T cells has identified
changes in a large number of lncRNAs (22), suggesting vital roles of lncRNAs in HIV-1
replication.
Here, we report the first genome-wide analysis of lncRNA expression in HIV-1-
infected primary monocyte-derived macrophages (MDMs). We identified an lncRNA,
which we named HIV-1-enhanced lncRNA (HEAL), that is conserved only in chimpanzees
and rhesus monkeys, suggesting that it is a recently emerged gene. We found that HEAL
regulates HIV-1 replication in microglia and T cells and does so by forming an RNA-
protein complex with FUS RNA-binding protein, which is specifically enriched at the
CDK2 promoter. HEAL-FUS complex positively regulates HIV transcription by recruit-
ment of histone acetyltransferase p300 to the HIV promoter. Moreover, HEAL expression
is elevated in peripheral blood mononuclear cells (PBMCs) from HIV-1-infected individ-
uals. Remarkably, HEAL silencing by RNAi or knockout by CRISPR-Cas9 in T cells and
microglia prevents recrudescence of HIV-1 upon withdrawal of azidothymidine (AZT)
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treatment in vitro. Thus, our results suggest that HEAL plays a vital role in HIV/AIDS
pathogenesis and could potentially be exploited as a therapeutic target.
RESULTS
Genome-wide lncRNA expression analysis of HIV-1-infected primary monocyte-
derived macrophages. To identify lncRNAs involved in HIV replication, we designed a
custom microarray. cDNA sequences of all known human lncRNAs were extracted from
two sources and used for probe design: 1,703 defined lncRNA transcripts were from the
Ensembl database and 2,915 transcripts were from the Havana database, as previously
reported (27). Overall, 5 to 8 probes were designed per transcript, and 26,000
commercially available mRNA probes were also included in the array for quality control.
To identify changes in lncRNA expression, MDMs from two healthy donors were
infected with the macrophage-tropic HIV-1BaL isolate, and RNA samples were prepared
for microarray analysis after 3 days. We confirmed the HIV-1 infection efficiency of these
cells by quantifying levels of GP120 mRNA (see below) as well as mRNAs representative
of the host antiviral immune response (interferon-induced guanylate-binding protein 1
[GBP1] and interferon-induced protein with tetratricopeptide repeats 1 [IFIT1]) (data not
shown). MDMs from both donors showed a more vigorous response to HIV-1 infection
at 3 days than at 6 days (data not shown); therefore, lncRNA expression was analyzed
at 3 days postinfection.
For analysis, lncRNAs were classified as HIV-1 modulated if their expression was
suppressed or induced in MDMs from both donors by at least 1.5-fold with a P value of
0.05. We identified 1,145 unique lncRNAs (1,866 probes) that satisfied these criteria,
of which 51% were suppressed and 49% were induced. A Circos plot was constructed
to show the differentially expressed coding genes and lncRNAs (Fig. 1A; see also
Table S1 in the supplemental material). The upregulated and downregulated genes are
shown in red and blue, respectively, and the lengths of the colored lines indicate the
log2 fold change in expression. As shown on the plot, the five lncRNAs with the highest
fold change in expression upon HIV-1 infection were linc02574-201, linc8790, linc7932,
linc4116, and linc5304. In addition, significant changes were observed in the expression
of coding genes involved in the host response to infection (Fig. 1A) (e.g., ISG15, STAT1,
OAS3, ISG20, CCL2, and MX1), confirming robust HIV-1 infection of these cells. We also
analyzed the expression of linc02574-201, the most significantly induced lincRNA, using
RT-qPCR and confirmed its upregulation upon HIV-1 infection of primary MDMs (Fig. 1B,
left). To determine whether linc02574-201 was also upregulated in HIV-1-infected T
cells, we examined two susceptible human CD4 T cell lines, MT4 (28) and H9 (29). Both
cell lines support infection with the T-cell-tropic HIV-1LAI isolate, but viral replication
peaks at a later time in H9 cells. RT-qPCR analysis showed that linc02574-201 was
upregulated by HIV-1 infection of MT4 cells at 2 days postinfection (Fig. 1B). In H9 T
cells, linc02574-201 expression was enhanced within 2 days of infection, reached a peak
on day 3, and remained elevated for several days (Fig. 1C). To evaluate whether
linc02574-201 regulation depends upon HIV replication, heat-inactivated HIV-1LAI virus
was inoculated in H9 cells and linc02574-201 was quantified at different time points.
During the 6-day period of analysis, linc02574-201 was not changed by inactivated
particles, indicating that HIV replication was essential for linc02574-201 upregulation in
T cells (Fig. 1D).
Expression of lncRNA HEAL correlates with HIV-1 replication. To confirm the
correlation between HIV-1 replication and linc02574-201 expression, we measured its
levels in a latently HIV-1-infected Jurkat T cell line, E4, which carries a single integrated
provirus and a short-lived variant of green fluorescent reporter protein (d2EGFP) in
place of the nef gene (30). Treatment of E4 cells with tumor necrosis factor alpha
(TNF-) to reactivate HIV-1 replication not only induced an increase in EGFP fluores-
cence, as expected, but also increased linc02574-201 transcription (Fig. 1E), confirming
the observations in H9 cells that this lincRNA is strongly associated with HIV-1 repli-
cation. To rule out the possibility that TNF- alone can induce linc02574-201 expres-
sion, we stimulated Jurkat cells with 100 ng/ml TNF- and analyzed lincRNA expression,
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and the results showed that TNF- did not affect linc02574-201 expression levels
(Fig. 1F). Therefore, we named linc02574-201 “HEAL” for HIV-1-enhanced lncRNA. Since
HEAL was the most highly upregulated lincRNA examined and was induced by both
HIV-1BaL and HIV-1LAI in primary MDMs and T cell lines, respectively, we further
investigated its potential role in HIV-1 replication.
FIG 1 Identification of lncRNAs associated with HIV-1 replication. (A) Circos plot showing differentially expressed coding
genes and lncRNAs in macrophages upon HIV-1 infection (P 0.1). The length of each line is proportional to the log2
fold change in gene expression. The genes are represented according to their chromosomal locations. Upregulated and
downregulated genes are shown in red and blue, respectively. As examples, six coding genes (ISG15, STAT1, OAS3,
ISG20, CCL2, and MX1) and five noncoding genes (linc02574-201, linc8790, linc7932, linc4116, and linc5304) are
indicated. (B) RT-qPCR analysis of linc02574-201 3 days after HIV infection of monocyte-derived macrophages (MDM)
(left) or 2 days after infection of MT4 cells (right). Signals were normalized to GAPDH mRNA levels. n 3, mean  SD;
*, P 0.05. (C and D) Kinetics of GP120 mRNA and linc02574-201 expression in HIV-infected (C) or heat-inactivated
HIV-inoculated (D) H9 cells. Signals were normalized to GAPDH mRNA levels. Results are the mean  SD from three
independent experiments. *, P 0.05; **, P 0.01; ***, P 0.001. (E and F) RT-qPCR analysis of GP120 mRNA and HEAL
(linc02574-201) RNA expression in latently infected E4 cells 18 h after TNF- treatment (E) or in Jurkat cells stimulated
with TNF- (3 ng/ml) for the indicated time points (F). Signals were normalized to GAPDH mRNA levels. Results are the
mean  SD from three independent experiments. *, P0.05; **, P0.01; ***, P0.001.
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lncRNA HEAL regulates HIV-1 replication. To determine the functional signifi-
cance of HEAL induction by HIV-1, we examined viral replication in T cells in which HEAL
expression was silenced by three short hairpin RNAs (shRNAs) targeting different
regions of HEAL. MT4 T cells were transduced with control (pLKO empty vector) or
shRNA-carrying lentiviruses for 2 days and then infected with HIV-1LAI for an additional
2 days, at which time HEAL RNA and HIV-1 GP120 mRNA were quantified by RT-qPCR.
All three shRNAs not only effectively silenced HEAL expression (Fig. 2A) but also
strongly reduced GP120 mRNA levels (Fig. 2B). To confirm this using an alternative
approach, H9 cells were transfected with an antisense oligonucleotide (ASO) targeting
HEAL. Here too, HEAL silencing reduced viral replication, as reflected by GP120 mRNA
levels, compared with cells transfected with a control ASO (Fig. 2C). We next asked
whether editing the genomic sequence of HEAL would inhibit HIV replication. MT4 cells
were transduced with Cas9 and single guide RNA (sgRNA) specific to HEAL exon2.
Similar to other strategies in Fig. 2B and C, editing HEAL also decreased HIV replication
(Fig. 2D). To investigate if HEAL could be a universal HIV enhancer, we knocked down
HEAL in a microglia cell line and infected it with HIVBaL, an R5-tropic strain, and the
results showed that replication of R5-tropic virus was decreased by HEAL silencing
(Fig. 2E). Additionally, replication of a dual-tropic virus (HIV89.6) was dependent on HEAL
expression (Fig. 2F). These results demonstrate that HEAL is a broad enhancer of HIV
replication. The finding that HEAL expression regulates HIV-1 prompted us to examine
its expression in host tissues with prominent roles in immunity. Interestingly, HEAL was
expressed in a very narrow range of tissues, with high expression being detected only
in adrenal glands, thymus, and skeletal muscle (Fig. S1A). Since the thymus is a
specialized primary lymphoid organ, this result provided further support for a link
between HEAL and HIV-1 replication.
Having established that HEAL silencing suppresses HIV-1 replication, we asked if the
inverse is true: can HEAL overexpression enhance HIV-1 replication? We first mapped
the full-length sequence of HEAL by performing 5= and 3= rapid amplification of cDNA
ends (RACE) (31, 32). We identified HEAL as a 467-bp transcript of gene RP11-288L9
located on human chromosome 1 (Fig. S1B). Only one transcript, the reverse strand
downstream of gene IFI6, was identified. However, KD of HEAL had no significant effect
on IFI6 expression (Fig. 2G), indicating that IFI6 was not the functional target of HEAL.
Next, we examined the effects of lentivirus-mediated overexpression of HEAL on HIV-1
infection in MT4 cells by examining GP120 expression 2 days after HIV-1 infection. We
found that HEAL overexpression upregulated HIV-1 replication compared with control
cells (Fig. 2H). Consistent with this, rescue experiments showed that HEAL reexpression
in HEAL KD cells increased GP120 mRNA levels (Fig. S1C). Taken together, the HEAL KD,
overexpression, and rescue experiments demonstrate an important functional role for
HEAL in HIV-1 replication. We performed a comparative genomic analysis of the HEAL
sequence in different species to determine whether HEAL is evolutionarily conserved.
Intriguingly, HEAL was highly conserved in only chimpanzees and rhesus monkeys,
suggesting that this lincRNA could be a recently emerged gene that is exploited by
HIV-1 (Fig. S1D). It is tempting to speculate that the narrow species expression of HEAL
might play an important role in host specificity for HIV-1 replication.
HEAL directly binds to the HIV-1 promoter. To investigate the mechanism by
which HEAL regulates HIV replication, chromatin isolation by RNA purification (ChIRP)
assays (32–34) were performed to assess HEAL binding to the HIV promoter. Chromatin
fractions from HIV-infected MT4 cells were incubated with biotinylated HEAL or control
partial lacZ (without protein-encoding potential) RNA and analyzed by RT-qPCR for the
presence of HIV promoter sequences. Three PCR primers (Nuc-0, HS, and Nuc-1)
spanning from 403 to 156 relative to the 1 transcription start site were designed
based on the nucleosome structure of the HIV-1 5= long terminal repeat (LTR) region
(Fig. 3A). We observed that biotinylated HEAL, but not GAPDH, mRNA was significantly
enriched compared to the lacZ probe (Fig. 3B, left), showing that specific HEAL ChIRP
was successful. Genomic glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
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FIG 2 An HIV-enhanced lincRNA transcript (HEAL), linc02574-201, regulates HIV-1 replication. (A and B)
Efficient silencing of HEAL in MT4 cells inhibits HIV-1 replication. MT4 cells expressing control vector or
one of three shRNAs targeting HEAL were infected with HIV-1. HEAL (A) and GP120 mRNA (B) were
quantified by RT-qPCR at 2 days postinfection. Signals were normalized to GAPDH mRNA levels. n 3,
mean  SD; *, P 0.05. (C) Antisense oligonucleotides targeting HEAL inhibit HIV-1 replication. H9 cells
were infected with lentiviruses encoding a nontargeting control (NTC) oligonucleotide or a HEAL-specific
antisense oligonucleotide (HEAL ASO) for 2 days and then infected with HIV-1. The cells were reseeded
for 3 days and then reinfected with NTC or ASO lentiviruses. Four days after the second ASO treatment,
GP120 mRNA levels were analyzed by RT-qPCR. Signals were normalized to GAPDH mRNA levels. n 3,
mean  SD; *, P 0.05; **, P 0.01. (D) sgRNA targeting HEAL inhibits HIV-1 replication. MT4 cells were
transduced with lentiviruses containing a nontargeting control sgRNA (sgNC) or a HEAL-specific sgRNA
(sgHEAL) for 7 days and then infected with LAI at an MOI of 0.025 or 0.5. GP120 mRNA levels were
measured by RT-qPCR 2 days after infection. n 3, mean  SD; **, P 0.01; ***, P 0.001. (E) Knock-
down of HEAL inhibits HIVBaL replication. Microglial cells expressing control vector or shHEAL-1 were
infected with HIVBaL. HEAL and GP120mRNAs were quantified by RT-qPCR at 9 days postinfection. Results
are the mean  SD from three independent experiments. Signals were normalized to GAPDH mRNA
levels. *, P 0.05; **, P 0.01. (F) Knockdown of HEAL inhibits HIV89.6 replication in primary PBMCs.
Activated primary PBMCs were transduced with control or shHEAL-1 lentivirus for 7 days. After activating
for the second time for 3 days, cells were infected with HIV89.6 at an MOI of 0.01. HEAL and GP120 mRNA
were quantified by RT-qPCR at 3 days postinfection. Signals were normalized to GAPDH mRNA levels.
n 3, mean  SD; **, P 0.01; ***, P 0.001. (G) HEAL knockdown did not affect IFI6 expression. IFI6
mRNA expression was quantified in MT4 cells expressing control vector or shRNA targeting HEAL. ns, not
significant. (H) Overexpression of HEAL enhances HIV-1 replication. HEAL was overexpressed in MT4 cells
using a pCDH lentiviral vector, and the cells were infected with HIV-1 2 days later. HEAL and GP120mRNA
levels were measured by RT-qPCR 2 days after infection. Signals were normalized to GAPDH mRNA levels.
n 3, mean  SD; **, P 0.01; ***, P 0.001.
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shown as a negative control (Fig. 3B, right). Importantly, RT-qPCR analysis of the
sequences pulled down with HEAL showed specific enrichment of the promoter regions
(Fig. 3B). These results indicate that HEAL directly binds to the HIV promoter in order to
regulate viral replication.
FIG 3 HEAL forms a complex with FUS protein and binds to HIV promoter. (A) Schematic of HIV promoter
regions based on nucleosome architecture. Primers to identify different regions of the promoter are
indicated. Nuc-0, nucleosome 0 region. HS, DNase I highly sensitive region. Nuc-1, nucleosome 1 region.
(B) HEAL is recruited to the HIV promoter. ChIRP assays were performed in HIV-infected MT4 cells using
a nonspecific lacZ probe or HEAL-specific probes. Specificity of HEAL probes (left) and enrichment at the
HIV promoter (right) are shown. GAPDH mRNA (left) or genomic GAPDH is shown as negative control.
Probes are listed in Table S4. Mean SD of n 3. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001;
ns, not significant. (C) Experimental design for purification and identification of HEAL-associated cellular
proteins using biotinylated HEAL or lacZ (control) RNA pulldown followed by mass spectrometry. (D)
Immunoblotting of FUS, vimentin, and DDX5 proteins identified from biotinylated lacZ and HEAL
pulldown assays. Vimentin and DDX5 are shown as negative controls. HEAL mRNA enrichment in
pulldown fraction was detected using qPCR. Mean  SD of n 3. ***, P 0.001. (E) FUS knockdown
inhibits HIV-1 replication. MT4 cells were infected with control lentivirus (empty vector, pLKO) or
lentiviruses carrying FUS-targeting shRNAs. Two days later, they were infected with HIV-1, and GP120
mRNA was quantified by RT-qPCR analysis after 2 days. Signals were normalized to GAPDH mRNA levels.
n 3, mean  SD; *, P 0.05; **, P 0.01. (F) FUS recruitment to the HIV promoter is dependent on
HEAL. HIV-infected control or HEAL knockdown MT4 cells were prepared for FUS-CHIP analysis. RT-qPCR
of the HIV promoter regions or GAPDH region coimmunoprecipitated with FUS was performed. Mean 
SD of n 3. *, P 0.05; **, P 0.01; ***, P 0.001.
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The RNA-binding protein FUS interacts with HEAL to regulate HIV replication.
Many lncRNAs have been shown to regulate gene expression by interacting with
RNA-binding proteins, transcription factors, or chromatin-modifying complexes (31, 32,
34, 35). We hypothesized that HEAL regulates HIV promoter activity by interacting with
RNA-binding proteins. To test this, we used an unbiased approach (Fig. 3C) in which
biotinylated HEAL or lacZ was incubated with MT4 cell lysates, and proteins associated
with the biotinylated RNAs were pulled down with streptavidin-conjugated beads,
eluted, and analyzed by mass spectrometry. The RNA-binding protein FUS (fused in
sarcoma) was identified as the most likely HEAL cofactor based on the number of
enriched peptides present in HEAL versus lacZ samples (Table S5). We verified that FUS
specifically interacts with HEAL by performing Western blot analysis of HEAL- and
lacZ-associated proteins. Indeed, FUS was present specifically in the HEAL pulldown
samples, whereas the intermediate filament protein vimentin and the RNA-binding
protein DDX5, probed as controls, were enriched in both HEAL and lacZ samples
(Fig. 3D). These results confirmed that HEAL and FUS can form a ribonucleoprotein
complex in vivo.
We next asked whether FUS could modulate HIV-1 replication. FUS expression was
silenced in MT4 cells using four different shRNAs, and the cells were then infected with
HIV-1. Knockdown of FUS dramatically decreased the levels of GP120 mRNA (Fig. 3E),
suggesting that FUS protein binds to HEAL to coregulate HIV transcription. To test this,
we performed chromatin immunoprecipitation (ChIP) analyses in HIV-1-infected control
and HEAL knockdown MT4 cells. After immunoprecipitation of endogenous FUS pro-
tein, the associated DNA was eluted and examined by RT-qPCR for the presence of HIV
promoter sequences. This analysis confirmed that FUS binds to the HIV promoter in
HIV-infected cells (Fig. 3F). Genomic GAPDH was not enriched and is shown as a
negative control (Fig. 3F, right). Importantly, compared to control cells, FUS binding on
HS and Nuc-1 regions was significantly decreased by FUS knockdown (Fig. 3F), further
supporting the existence of a HEAL-FUS-HIV regulatory axis that controls HIV-1 repli-
cation.
HEAL-FUS complex recruits p300 to increase the H3K27ac modification and
P-TEFb loading on the HIV promoter. During active HIV transcription in cells, histone
acetyltransferase (HAT) complex is recruited to the HIV promoter region that acetylates
histone residues, leading to enhanced transcription (36–38). FUS has been shown to
interact with HAT complex members, including p300, CBP, and TIP60 (39). Based on the
findings that FUS-HEAL complex binds to the HS and Nuc-1 regions of the HIV promoter
(Fig. 3F), we hypothesized that FUS-HEAL complex might enhance HAT complex
recruitment to the HIV promoter. To test this hypothesis, we performed p300-CHIP and
H3K27ac-CHIP in control and HEAL knockdown T cells infected with HIV. Our results
showed that p300 recruitment and H3K27ac modification were significantly decreased
in HEAL-depleted cells, especially in HS and Nuc-1 regions, which correspond to
HEAL-FUS complex binding regions (Fig. 3F and Fig. 4A and B). Control experiments
showed that H3K27ac modification in the GAPDH genomic region was unchanged by
HEAL knockdown (Fig. 4B). These results suggested that HEAL-FUS complex facilitated
the binding of p300 acetyltransferase to the HIV promoter, thus enhancing H3K27ac
modification and HIV transcription. During HIV transcription, a positive transcription
elongation factor, P-TEFb, binds HIV Tat-TAR RNA complex to relieve elongation blocks
by phosphorylating RNA polymerase (Pol) II and negative elongation factors such as
SPT5 and SDIF (37, 38, 40, 41). To further confirm whether HIV transcription was
enhanced by HEAL, we analyzed the binding of a P-TEFb subunit, cyclin T1, on the HIV
promoter. Our CHIP-qPCR experiments showed that cyclin T1 was significantly enriched
on the HS and Nuc-1 regions of the HIV promoter, with a higher binding in the Nuc-1
region than the HS region as predicted from the elongation function of P-TEFb (Fig. 4C).
Importantly, cyclin T1 binding was significantly reduced in HEAL KD cells (Fig. 4C).
Altogether, these results demonstrate that HEAL plays an important role in enhancing
p300 binding to the HIV promoter and positively regulating HIV transcription.
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HEAL stimulates CDK2 expression. We next sought to shed light on the mecha-
nism by which HEAL might regulate HIV-1 replication by identifying host genes whose
expression is controlled by HEAL. MT4 cells were transduced with HEAL-targeting or
control shRNAs for 2 days and then infected with HIV-1. Genome-wide mRNA analysis
was performed 2 days postinfection using a human HT-12 v4 expression BeadChip kit,
which contains 47,000 probes derived from the NCBI RefSeq release 38, among other
sources. Candidate HEAL-modulated genes were selected based on (i) the fold change
(P 0.05) in their expression in HIV-1-infected MT4 cells expressing control versus
HEAL-specific shRNA and (ii) the number of detected probes. Fifty percent of genes of
the top hit were identified in both of the two HEAL KD cells. Fifteen genes showed
decreased expression in HEAL KD HIV-1-infected cells, suggesting that they may be
FIG 4 HEAL-FUS complex recruits histone acetyltransferase p300 to modulate histone modification and
P-TEFb enrichment at the HIV promoter. HIV-infected control or HEAL knockdown MT4 cells were
prepared for CHIP analyses—p300 (A), H3K27ac (B), and cyclin T1 (C)—as described in the legend to
Fig. 3F. Results of RT-qPCR of the HIV promoter regions enriched for p300, H3K27ac, and cyclin T1 are
shown in panels A, B, and C, respectively. Mean SD of n 3. *, P 0.05; **, P 0.01; ***, P 0.001; ****,
P 0.0001; ns, not significant.
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regulated by HEAL. Of these 15 genes, 9 were further validated by RT-qPCR analysis and
shown to be upregulated in HIV-1-infected MT4 cells (Fig. 5A and Tables S2 and S3) and
reduced by HEAL KD (Fig. 5B), consistent with the expected behavior of HEAL-regulated
genes. CT45A4, which was not affected by HIV-1 infection in our genome-wide analysis,
was used as a control for these experiments.
To determine whether HEAL regulates gene expression by direct interaction with
promoters, we performed ChIRP assays. For this, biotinylated HEAL or control (lacZ) RNA
FIG 5 HEAL is required to maintain expression of CDK2 to support HIV-1 replication. (A) RT-qPCR analysis
of HEAL-regulated mRNAs in uninfected or HIV-1-infected MT4 cells 2 days postinfection. Signals were
normalized to GAPDH mRNA levels. n 3, mean  SD; *, P 0.05; **, P 0.01. (B) RT-qPCR analysis of
HEAL-regulated mRNAs in MT4 cells expressing control vector or three HEAL shRNAs and then infected
with HIV-1. mRNAs were quantified 2 days later. Signals were normalized to GAPDH mRNA levels. n 3,
mean  SD; *, P 0.05; **, P 0.01. (C) qPCR of HEAL-associated DNA in ChIRP assays of uninfected or
HIV-1-infected MT4 cells expressing empty vector (control) or overexpressing HEAL. n 3, mean  SD;
*, P 0.05. (D) FUS protein interaction with the CDK2 promoter is enhanced by HIV-1 infection. ChIP
assays of H9 T cells 7 days after infection with HIV-1. RT-qPCR analysis of the CDK2 promoter region was
performed on control IgG or anti-FUS immunoprecipitates. Signals were normalized to GAPDH mRNA
levels. n 3, mean  SD; *, P 0.05; **, P 0.01; ****, P 0.0001. (E) RT-qPCR analysis of GP120 and
CDK2 mRNA in HIV-1-infected MT4 cells expressing empty vector (pCDH) or overexpressing HEAL. Signals
were normalized to GAPDH mRNA levels. n 3, mean  SD; *, P 0.05; ***, P  0.001. (F) Knockdown
of HEAL or FUS reduces cellular CDK2 protein levels. MT4 cells were transduced with lentiviruses carrying
empty vector or the indicated shRNAs and infected with HIV-1 2 days later. Cell lysates were prepared
2 days after infection and analyzed by Western blotting with anti-CDK2 or anti--actin antibodies.
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was incubated with the chromatin fraction of uninfected or HIV-1-infected MT4 T cells,
and the RNA was then pulled down with streptavidin-conjugated beads (Fig. S2A). DNA
coprecipitated with HEAL or lacZ RNA was recovered and analyzed by qPCR. As shown
in Fig. 5C, the CDK2 promoter sequence was specifically pulled down by HEAL in
HIV-1-infected cells but not in uninfected cells, identifying CDK2 as a bona fide HEAL
target. To investigate whether HEAL-FUS complex plays a role in CDK2 regulation, we
performed a FUS-ChIP assay in mock- and HIV-infected cells. As shown in Fig. 5D, FUS
could significantly bind the CDK2 promoter and was enhanced in HIV infection. These
results confirmed HEAL-FUS complex as regulating CDK2 expression. Additionally, HEAL
overexpression increased CDK2mRNA levels (Fig. 5E) while HEAL and FUS KD decreased
CDK2 protein levels (Fig. 5F) in HIV-1-infected MT4 cells. Since the CDK2 activation
requires its interaction with cyclin A (42), we investigated whether the decrease in CDK2
expression affects the formation of functional complexes of CDK2. We performed cyclin
A immunoprecipitation to analyze the CDK2-cyclin A interactions in nontargeting
shRNA control (NC) and HEAL KD cells. Our results showed that CDK2-cyclin interactions
were not affected by HEAL KD, suggesting that CDK2 was functional in these KD cells
(Fig. S2B). Collectively, these results demonstrate that HEAL-FUS complex binds to the
promoter of CDK2 and regulates its expression.
HEAL silencing prevents reactivation of HIV-1 replication in T cells and micro-
glial cells after cessation of AZT treatment. To determine whether HEAL expression
is related to the level of HIV-1 infection in vivo, we compared its expression in PBMCs
from 48 viably stored blood samples collected from 33 HIV-1-infected individuals.
RT-qPCR analysis of PBMCs showed that both HEAL and CDK2 mRNA expression was
upregulated by HIV-1 infection, consistent with the findings in H9 and MT4 T cell lines
(Fig. 6A and B).
Our finding that shRNA-mediated suppression of HEAL concomitantly inhibited
HIV-1 replication in T cells suggests that HEAL silencing may effect a functional cure. We
designed a strategy to determine the relationship between HEAL expression and viral
rebound, a well-established clinical consequence of withdrawal from AZT therapy. H9
cells were infected with control or HEAL shRNA-carrying lentiviruses for 3 days and then
infected with HIV-1 for 5 days. The cells were then treated with AZT for 3 days (first
treatment), washed, and placed back in culture in AZT-free or AZT-containing medium
(second treatment) for a further 3 days. HEAL RNA and GP120 mRNA levels were
quantified on days 11 and 14, after the first and second AZT/control treatments
(Fig. 6C). We found that HIV-1 replication was effectively suppressed in cells expressing
the shRNA control vector (pLKO) and treated with AZT for the entire 6 days (i.e., first and
second treatments). However, removing AZT after the first treatment led to a dramatic
rebound in HIV-1 replication, consistent with clinical observations (bars 1 to 3, Fig. 6D).
Remarkably, HIV-1 replication remained suppressed in HEAL KD cells when AZT was
removed (bars 5 and 6, Fig. 6D). In accord with results shown in Fig. 1 and 2, HEAL RNA
expression correlated with HIV replication (Fig. 6D and E). This effect was confirmed in
human microglial cells, where GP120 expression could not be rescued by removal of
AZT in HEAL KD cells (Fig. S3). Taken together, these results suggest that HEAL silencing
might be exploited therapeutically to prevent HIV-1 rebound replication when ART is
discontinued.
HEAL deletion by CRISPR prevents rebound of HIV-1 replication upon ART
withdrawal. To further confirm the HEAL RNAi results (Fig. 6C and D) and determine
the therapeutic potential of CRISPR-Cas9 to generate HEAL KO cells, we deleted HEAL
in H9 cells by CRISPR-Cas9-mediated editing using an sgRNA targeting HEAL exon 2
(Fig. 7A). HEAL knockouts and control cells were obtained through single-cell clonal
expansion of H9 cells transfected with HEAL or control sgRNA. Positive clones were
identified by T7 endonuclease I (T7EI) assay, which generated two editing segments
(275 bp and 866 bp) (Fig. S4A). We also amplified and sequenced the genomic region
around the editing site and confirmed biallelic modification of the HEAL locus (Fig. S4B).
Next, we performed HIV-1 rebound replication assays similar to the one described
for Fig. 6C. We found that HIV-1 replication was effectively suppressed (80-fold) in
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HEAL/ cells compared with control cells and remained suppressed on days 11 and 14
after AZT removal (Fig. S4C). To test the long-term effect of HEAL knockout on
suppression of HIV-1 rebound replication, we examined cultures 28 days after AZT
withdrawal. HEAL/ H9 cells or control cells were infected with HIV-1 at multiplicities
of infection (MOIs) of 0.025 or 0.5 for 5 days, treated with AZT for 3 days (first
treatment), washed, and then cultured in AZT-free or AZT-containing medium for a
further 28 days (second treatment; Fig. 7B). HIV-1 replication was effectively suppressed
in HEAL/ cells, with 280-fold and 40-fold inhibition in cells infected at MOIs of
0.025 and 0.5, respectively. Remarkably, HIV-1 replication remained suppressed in
HEAL/ cells, even when AZT had been removed 28 days earlier (Fig. 7C and D).
Collectively, these results suggest that inhibition of HEAL expression could be a
potential therapy to prevent HIV-1 replication.
FIG 6 HEAL silencing maintains HIV-1 suppression after AZT withdrawal. (A and B) HEAL (A) and CDK2
(B) expression levels were increased in PBMCs of HIV-1-infected individuals. HEAL (A) and CDK2 (B)
expression levels were measured by RT-qPCR, and signals were normalized to GAPDH mRNA levels. Data
were calculated using the threshold cycle (2ΔΔCT) method and analyzed with Student’s t test. *, P 0.05;
****, P 0.0001. (C to E) Experimental design for the analysis of HIV-1 replication in HEAL-depleted and/or
AZT-treated cells. H9 T cells were infected with control or HEAL shRNA-carrying lentiviruses, maintained
under puromycin selection conditions for 3 days, and then infected with HIV-1. Cells were treated with
AZT (0 to 20 M) between days 8 and 11 and then either switched to AZT-free medium or maintained
in medium containing 0 to 20 M AZT for an additional 3 days (C). On day 14, cells were collected and
analyzed for GP120 mRNA (D) or HEAL RNA (E) by RT-qPCR. Signals were normalized to GAPDH mRNA
levels. n 3, mean  SD; *, P 0.05; **, P 0.01; ***, P 0.001; ns, not significant.
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DISCUSSION
In this study, we systematically analyzed changes in the expression of lncRNAs upon
HIV-1 infection of macrophages and MT4 and H9 T cells. Through a combination of
genomic, biochemical, and cell biological approaches, we identified the novel lincRNA
HEAL as a key player in controlling HIV-1 replication in macrophages, microglia, and T
cells. We first found that HIV-1 infection markedly upregulated the expression of several
lincRNAs in the T cell lines, of which HEAL, linc8790, linc7932, linc4116, and linc5304
were the most increased in MT4 cells, whereas HEAL, linc4116, and linc5304 were most
highly increased in H9 cells (data not shown). These minor differences in upregulation
suggest that the effect of HIV-1 on lncRNA expression may vary between different cells.
The demonstration that HEAL expression is tissue and species specific supports the
notion that it is a recently emerged gene and may contribute to the species restriction
of HIV-1 replication (see Fig. S1A and D in the supplemental material).
HEAL expression was significantly upregulated in H9 at 2 days postinfection (Fig. 1C),
while heat-inactivated virus did not change HEAL expression (Fig. 1D). These results
suggest that the upregulation is not dependent on viral entry. Furthermore, in the
cellular model of latent HIV infection, HEAL is induced upon HIV activation (Fig. 1E).
FIG 7 HEAL knockout maintains HIV-1 suppression after AZT withdrawal. (A) Location of the guide RNA used for
CRISPR-Cas9-mediated editing of the HEAL locus in H9 cells. Arrows indicate the primers used to amplify the
genomic region harboring the editing site. Red lines indicate the segments amplified and the segments predicted
to be present in positive clones after T7EI digestion. (B) Experimental design for the analysis of HIV-1 replication
in HEAL/ or control cells. H9 T cells were infected with control or HEAL sgRNA-carrying lentiviruses, maintained
under puromycin selection conditions for 4 days, and then infected with HIV-1 at an MOI of 0.025 or 0.5. Cells were
treated with AZT (20 M) between days 25 and 28 and then switched to AZT-free or 20 M AZT-containing
medium for an additional 28 days. On day 56, cells were collected and analyzed. (C and D) RT-qPCR analysis of
GP120 mRNA in H9 cells infected at an MOI of 0.025 (C) or 0.5 (D). Signals were normalized to GAPDH mRNA levels.
n 3, mean  SD; *, P  0.05; **, P  0.01; ***, P 0.001; ****, P 0.0001.
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These results confirm that HEAL regulation is dependent on HIV replication. Further
studies are needed to define the precise triggers and signaling mechanism by which
HEAL expression is induced after HIV-1 infection.
To our knowledge, HEAL is the first lncRNA that directly binds to the HIV promoter
at the Nuc-0, HS, and Nuc-1 regions (Fig. 3A and B). We further demonstrated that
HEAL-FUS formed an RNP complex to regulate HIV transcription (Fig. 3C to F). Here, the
binding of FUS on the HIV promoter was dependent on HEAL at HS and Nuc-1 regions
but not at the Nuc-0 region (Fig. 3F). One possibility is that as HEAL has different
domains that function in binding the HIV promoter and/or interacting with FUS and
that HEAL binding on genomic DNA at the Nuc-0 region interferes with the FUS-
interacting domain or alters FUS conformation for the ChIP quantification.
Processive transcription from the HIV promoter is dependent on the function of
P-TEFb that interacts with HIV Tat-TAR complex (37, 41, 43). P-TEFb is composed of two
subunits, called cyclin T1 and CDK9 (37, 41, 43). Cyclin T1 binding near the TAR region
was significantly decreased when HEAL expression was silenced (Fig. 4C). Together with
the results that p300 as well as activation histone marker H3K27ac on HIV promoter was
increased by HEAL (Fig. 4A and B) and that FUS interacts with HAT complex (39), we
propose that HEAL-FUS complex was specifically enriched at the HIV promoter to
enhance p300 recruitment and HIV transcription. Altogether, these results identified a
new mechanism of an HIV-induced lncRNA, HEAL, that enhances HIV replication by
directly binding to the HIV promoter and regulating its transcription by histone
modification (Fig. 8).
HEAL regulates CDK2 expression in T cells through a direct interaction with the
transcription factor FUS (Fig. 5). Increased CDK2 levels could enhance HIV-1 replication
via several mechanisms. First, CDK2 has been shown to be an essential regulator of
HIV-1 replication through phosphorylation and inactivation of SAMHD1, a phosphohy-
drolase that reduces the availability of deoxynucleoside triphosphates, thereby restrict-
ing HIV-1 replication. Inactivation of SAMHD1 thus increases the deoxynucleoside
triphosphate pool available for HIV-1 reverse transcriptase and replication (44). Second,
CDK2 phosphorylates serine 90 of CDK9, a component of the positive transcription
elongation factor P-TEFb, supporting a role for CDK2 in the regulation of HIV-1
transcription (45). Third, efficient HIV-1 replication requires CDK2-mediated phosphor-
ylation of a highly conserved threonine residue in the viral reverse transcriptase (46).
CDK2-dependent phosphorylation thus enhances viral fitness by increasing the efficacy
and stability of the reverse transcriptase (46). In addition, CDK2 can directly interact
FIG 8 Proposed mechanism for HEAL- and FUS-mediated regulation of HIV-1 replication. HIV-1 infection
enhances expression of HEAL, which interacts with FUS protein and increases HEAL-FUS binding at the HIV
promoter. HEAL-FUS complex recruits histone acetyltransferase p300 to enhance H3K27ac modification,
leading to P-TEFb enrichment on the HIV promoter and processive transcription. See the text for details.
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with FUS, as found in human embryonic stem cells (47), to potentially modulate
FUS-mediated transcription and chromatin-remodeling functions. Our results showing
that CDK2 expression is upregulated in HIV-1-infected patients further support an
important role for this kinase in viral replication. This study thus identifies a new
mechanism for HIV-1 regulation of CDK2 expression through enhanced transcription of
the lncRNA HEAL.
We hypothesize that under ART, HEAL maintains a low level of expression that can
be rapidly upregulated to reactivate viral replication when cells emerge from latency.
HEAL expression targets the HIV promoter and enhances viral transcription by histone
acetyl modification and elongation by P-TEFb. Our data showing that HEAL is elevated
by HIV-1 infection in both MDMs and T cells demonstrated that targeting HEAL prevents
viral recrudescence in both cell types when AZT is discontinued. Indeed, our data also
suggest that inhibition of CDK2 is another potential strategy by which viral replication
could be suppressed after ART cessation. Although no specific CDK2 inhibitors have
been designed to date, targeting HEAL could indirectly inhibit CDK2 without influenc-
ing its other critical functions. Further studies are needed to define the precise signaling
mechanism by which HEAL expression is induced after HIV-1 infection and how its
expression is restricted during viral latency.
MATERIALS AND METHODS
Blood samples. Peripheral blood from HIV-1-infected donors was collected into PAXgene tubes, and
PBMCs were isolated as described below. RNA was isolated using TRIzol (Invitrogen) according to the
manufacturer’s instructions. Parental or patient informed consent was obtained for all donors under a
protocol approved by the Human Research Protection Program at UCSD.
Cell culture. MT4 and H9 cells were cultured in RPMI (Mediatech) containing 10% fetal bovine serum
(FBS) and 50 M -mercaptoethanol (Sigma). E4 Jurkat cells were cultured in RPMI containing 10% FBS,
penicillin-streptomycin, and 25 mM HEPES. MDMs were prepared by culture of PBMCs (see below) in
RPMI containing 10% human serum for 1 week before seeding for experiments. 293FT cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) with 10% FBS.
PBMC isolation. A buffy coat fraction (25ml) prepared by low-speed centrifugation of blood was
centrifuged over Ficoll-Paque Plus (GE Healthcare) according to the manufacturer’s recommendations. The
PBMC-containing interface layer was removed and washed with phosphate-buffered saline (PBS)–0.1% BSA
followed by PBS. Cells were then collected and used for MDM preparation (above) or for RNA isolation.
shRNA design and vector construction. Sense and antisense sequences of shRNAs were designed
using the open-access small interfering RNA (siRNA) selection program (48). shRNAs were obtained from
Integrated DNA Technologies and cloned into the pLKO.1-puro lentiviral vector (Addgene) according to
the manufacturer’s instructions. shRNA sequences are listed in Table S4 in the supplemental material.
shRNAs targeting FUS were purchased from Thermo Fisher Scientific. For gene cloning, EGFP and HEAL
were cloned into the pCDH-EF1-MCS lentiviral vector (System Biosciences; catalog no. CD502A-1) using
the primers listed in Table S4.
Lentivirus production and transduction. 293FT cells were seeded in 6-well plates at 8	 105/well
1 day before transfection. The culture medium was changed to Opti-DMEM (Life Technologies) before
transfection. Lentiviral vectors were mixed with packaging vectors (System Biosciences) and transfected
into 293FT cells using Lipofectamine 2000 (Invitrogen; catalog no. 11668019) according to the standard
protocol for Opti-DMEM. The medium was replaced with DMEM containing 10% FBS 6 h after transfec-
tion. Two days after transfection, virus supernatants were collected and centrifuged at 4,000 rpm for
5 min to remove debris. For virus transduction, MT4 cells were seeded in 12-well plates at 4	 105
cells/well; infected by the addition of 500 l virus supernatant, 4 g/ml Polybrene, and 500 l fresh
medium; and then centrifuged at 750 rpm for 45 min at room temperature. The medium was refreshed
the next day, and the cells were cultured for at least 3 days before analysis.
HIV-1LAI and HIV-1BaL production and transduction. 293FT cells were seeded in 10-cm plates at
3	 106/well 1 day before transfection. The pLAI.2 or pBaL.01 vector was transfected into 293FT cells
using Lipofectamine 2000 at a 1:2.5 ratio. Two days after transfection, virus supernatants were collected
and centrifuged at 4,000 rpm for 5 min to remove debris. For HIV-1 transduction, MT4 or H9 cells were
seeded in 12-well plates at 4	 105 cells/well and infected by the addition of 100 l virus supernatant and
400 l fresh medium for 4 h. The medium was refreshed, and the cells were cultured for at least 2 days
(MT4) or 7 days (H9) before analysis.
CRISPR-Cas9 editing of the HEAL locus. The strategy to target HEAL exon2 with guide RNA is
depicted in Fig. 6A. Briefly, guide sequences (HEAL, CCTCTTCCAGCCATTTATCCGTC; control, CGGAGGCT
AAGCGTCGCAA) were generated as single-stranded oligonucleotides and annealed for cloning into
lentiCRISPR v2 (Addgene 52961) according to previously published methods (34). Positive clones
containing guides were identified by sequencing, and 1.8 g of guide RNA vectors was transfected into
293FT cells to produce lentivirus. H9 cells were transduced with lentivirus, 1.0 g/ml puromycin was
added 24 h later, and the cells were cultured for 48 h. The surviving cells were cloned at 0.5
cells/100 l/well in 96-well plates and cultured for 2 weeks. Single colonies were picked and screened
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using T7EI analysis (New England BioLabs [NEB]; catalog no. number E3321). Positive knockout clones
were then sequenced to confirm biallelic modification of the HEAL locus.
RNA extraction and RT-qPCR analysis. Total RNA was extracted with TRIzol according to the
manufacturer’s instructions. RNA was precipitated and dissolved in diethyl pyrocarbonate (DEPC)-treated
water. Aliquots of 2 g of total RNA were treated with Turbo DNase (Ambion) to remove contaminating
genomic DNA, and the DNase-treated RNA was reverse transcribed using the iScript cDNA synthesis kit
(Bio-Rad). qPCR was performed using 2	 SYBR green mix (Bio-Rad) with cycling conditions of 95°C for
5 min followed by 50 cycles of 95°C for 10 s, 60°C for 10 s, and 72°C for 10 s. All qPCR primer sequences
are listed in Table S4.
lncRNA microarray design and analysis. lncRNA microarrays were designed and prepared as
described previously (31). Briefly, cDNA sequences of human lncRNAs were collected from two databases:
1,703 defined lncRNA sequences were downloaded from Ensembl (release 61) and 2,915 were down-
loaded from Havana (27). cDNA sequences were uploaded into the Agilent eArray custom microarray
design system, and probes of 60 nucleotides in length were designed by the software. Probes with the
potential for cross-hybridization were removed. In total, we obtained 12,281 probes for the 1,578 human
lncRNA sequences from the Ensembl database and 15,947 probes for the 2,827 sequences from the
Havana database. The probes were used to generate a custom microarray from Agilent. For quality
control, 26,000 commercially available mRNA probes were also included in the array (Table S1).
Rapid amplification of cDNA ends. To deplete rRNA, total RNA isolated from MT4 cells was
processed using a Ribo-Zero rRNA removal kit according to the manufacturer’s user manual (Epicentre).
RACE was performed using a SMARTer RACE kit (Clontech) according to the manufacturer’s instructions.
Briefly, 100 ng of purified poly(A) RNA was used for each RT-PCR. lncRNA cDNA samples (20 l) were
diluted10-fold and used for nested PCRs. One primer was used for 3= RACE, and two primers were used
for 5= RACE. Primer sequences are given in Table S4.
Chromatin isolation by RNA purification. MT4 cells (4	 107) were collected and fixed with 1%
glutaraldehyde in 40 ml PBS for 10 min at room temperature, and the reaction was quenched by addition
of 4 ml of 1.25 M glycine for 5 min at room temperature. The samples were centrifuged at 2,000 relative
centrifugal force (RCF) for 5 min and washed twice with cold PBS, and the pellets were flash-frozen in
liquid nitrogen and stored at 80°C. The pellets were thawed, mixed with 10 volumes of lysis buffer
(50 mM Tris-HCl, pH 7.0, 10 mM EDTA, 1% SDS), and sonicated in a 4°C water bath at the highest setting
for intervals of 30 s on and 45 s off for a total of 2 h. The cell lysate was centrifuged at 16,100 RCF for
10 min at 4°C, and the supernatant was collected. For the pulldown assay, the chromatin extract was
mixed with 2 volumes of hybridization buffer and incubated with 2 g biotinylated and folded in
vitro-transcribed RNA for 4 h at 37°C with shaking. After hybridization, samples were incubated with 40 l
streptavidin-conjugated beads for 1 h with shaking, and the DNA and RNA were eluted from the beads
as previously described (33, 34).
Biotinylation of RNA and RNA-protein pulldown assays. linc0492 and lacZ were cloned into
pBluescript KSII downstream of the T7 promoter. The plasmid was linearized by single digestion with
EcoRI, and 1 g of linear RNA was transcribed and biotin labeled in vitro using an AmpliScribe-T7-Flash-
biotin-RNA transcription kit (Epicentre) according to the manufacturer’s instructions. MT4 cells (4	 107)
were resuspended in 4 ml of kit buffer A, and the RNA-protein pulldown assays were performed
according to published methods (31).
Chromatin immunoprecipitation. Uninfected or HIV-1-infected H9 or MT4 cells (2	 107) were
collected and fixed in 1% formaldehyde for 10 min at room temperature, and the reaction was quenched
by addition of 125 mM glycine. Rabbit anti-FUS antibody (ab84078; Abcam) was used to immunopre-
cipitate endogenous FUS protein for ChIP assays. Anti-cyclin T1 antibody (81464; Cell Signaling Tech-
nology [CST]), anti-p300 (ab14984; Abcam), and anti-H3K27ac (ab4729; Abcam) were used to immuno-
precipitate target proteins for ChIP assays. Rabbit IgG (2729; CST) was used as isotype control. and
isotype control assays were performed according to published methods (49).
Western blotting. Cell lysates or immunoprecipitated products were separated by 10% SDS-PAGE
and transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with 5%
nonfat milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) and incubated with primary
antibodies overnight at 4°C. Blots were washed and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies for 1 h at room temperature. Finally, blots were washed and visualized
with ECL substrate (Pierce). Antibodies and dilutions were rabbit anti-HA (hemagglutinin)-tag monoclo-
nal antibody (MAb) (C29F4) at 1:1,000 (Cell Signaling; 3724S), mouse anti-FLAG M2 antibody at 1:1,000
(Sigma-Aldrich; F1804), mouse anti-FUS MAb (4H11) at 1:200 (Santa Cruz; sc-47711), rabbit anti-CDK2
MAb (78B2) at 1:1,000 (Cell Signaling; S2546P), rabbit anti-DDX5 at 1:2,000 (Abcam; ab21696), and mouse
antivimentin at 1:2,000 (Abcam; ab8978). Secondary antibodies were anti-mouse IgG (Santa Cruz;
SC-2031) and anti-rabbit IgG (Pierce), both at 1:2,000.
Statistical analysis. Comparisons between two groups were analyzed using the Student t test. The
differences were considered statistically significant when P was0.05 (*, P 0.05; **, P 0.01; ***,
P 0.001; ****, P 0.0001). Data are presented as mean  SD.
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